Insulet Corp. closed $9.41 below its 52-week high ($279.77), which the company achieved on December 12th.

Bernstein raised the firm’s price target on Insulet (PODD) to $315 from $305 and keeps an Outperform rating on the shares as part of a broader ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Buying $100 In PODD: If an investor had bought $100 of PODD stock 10 years ago, it would be worth $598.02 today based on a ...

Shares of Insulet Corp. PODD shed 1.03% to $265.65 Tuesday, on what proved to be an all-around grim trading session for the ...

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for those with Type 2 diabetes. The system ...

Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet (PODD – Research Report) yesterday and set a price target of ...

In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Insulet (PODD – Research Report), with a price target of ...

Insulet (NASDAQ:PODD – Get Free Report) had its target price increased by investment analysts at TD Cowen from $264.00 to ...

Insulet Corporation ( NASDAQ:PODD ) saw a double-digit share price rise of over 10% in the past couple of months on ...